Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


Product Candidates Under Development

HEMISPHERx BIOPHARMA, Inc. has developed over nearly three decades a vast body of knowledge relating to a potentially new class of pharmaceutical products (nucleic acid compounds) that are designed to activate otherwise dormant cellular defenses against viruses and tumors. We pursue commercialization of our products and have a strong and broad-based patent base.
 
 
 

Indication

Product Candidate

Status

CFS/ME

Ampligen®

Phase III Double Blind Study Completed

CFS/ME

Ampligen®

Phase III Treatment Protocol Ongoing

Influenza Vaccine Adjuvant

Ampligen®

Phase I/II Study Ongoing

Influenza Treatment

Alferon® LDO

Phase II Study In Preparation

Influenza Prevention

Alferon® LDO

Phase I/II Study In Preparation

Thermal Injury

Ampligen®

Phase I/II Study In Preparation

Breast Cancer

Ampligen®

Phase I/II Study Ongoing

Ovarian Cancer

Ampligen®

Phase I/II Study In Preparation

Peritoneal Cancer

Ampligen®

Phase I/II Study In Preparation

Colorectal Cancer

Ampligen®

Phase I/II Study Ongoing